Carlos Mesía

A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01)

Carmen Balañá, María Ángeles Vaz Salgado, Juan Manuel Sepúlveda-Sánchez et al. · Neuro-Oncology · 2020 · 107 citations · Full text

Medicine, Oncology, Radiation Oncology +17

Bevacizumab for the Treatment of Glioblastoma

Miguel Gil‐Gil, Carlos Mesía, Montserrat Rey et al. · Clinical Medicine Insights Oncology · 2013 · 88 citations · Full text

Medicine, Oncology, Pharmacology +14

Pseudoprogression as an adverse event of glioblastoma therapy

Carmen Balañá, Jaume Capellades, Estela Pineda et al. · Cancer Medicine · 2017 · 58 citations · Full text

Medicine, Neurology, Oncology +14

Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study

Miguel Gil‐Gil, Meritxell Bellet, Serafín Morales et al. · Breast Cancer Research and Treatment · 2015 · 52 citations

Medicine, Oncology, Pharmacology +17

Contrast-enhancement in supratentorial low-grade gliomas: a classic prognostic factor in the molecular age

Florian Castet, Enrique Alanya, Noemí Vidal et al. · Journal of Neuro-Oncology · 2019 · 44 citations

Medicine, Oncology, Radiology +16